{"id":27698,"date":"2024-07-26T09:21:53","date_gmt":"2024-07-26T09:21:53","guid":{"rendered":"https:\/\/kraios.app\/news\/saglik\/2024\/07\/26\/turkiye-lenf-kanseri-hastalari-icin-yurutulen-yeni-akilli-ilac-calismasina-oncu-oldu\/"},"modified":"2024-07-26T09:21:53","modified_gmt":"2024-07-26T09:21:53","slug":"turkiye-lenf-kanseri-hastalari-icin-yurutulen-yeni-akilli-ilac-calismasina-oncu-oldu","status":"publish","type":"post","link":"https:\/\/kraios.app\/news\/saglik\/2024\/07\/26\/turkiye-lenf-kanseri-hastalari-icin-yurutulen-yeni-akilli-ilac-calismasina-oncu-oldu\/","title":{"rendered":"T\u00fcrkiye, lenf kanseri hastalar\u0131 i\u00e7in y\u00fcr\u00fct\u00fclen yeni “ak\u0131ll\u0131 ila\u00e7” \u00e7al\u0131\u015fmas\u0131na \u00f6nc\u00fc oldu"},"content":{"rendered":"

<\/p>\n

\n

Yakla\u015f\u0131k 7 ay \u00f6nce \u00fcniversitenin Cebeci yerle\u015fkesinde hizmete ba\u015flayan ve ge\u00e7en g\u00fcnlerde ilk g\u00f6n\u00fcll\u00fc taramas\u0131n\u0131 ger\u00e7ekle\u015ftiren Faz-1 Klinik Ara\u015ft\u0131rma Merkezi, kap\u0131lar\u0131n\u0131 AA ekibine a\u00e7t\u0131.<\/p>\n

Sadece yetkililerin kendilerine tan\u0131ml\u0131 kartla giri\u015f yapabildi\u011fi, 24 saat esas\u0131na g\u00f6re izlenen merkezde, hasta odalar\u0131n\u0131n yan\u0131 s\u0131ra eksi 80 dereceye kadar dayan\u0131kl\u0131 \u00f6zel so\u011futmal\u0131 dolaplar ve ara\u015ft\u0131rma odalar\u0131 bulunuyor.<\/p>\n

\"\"<\/p>\n

Burada, klinik ara\u015ft\u0131rma \u00fcr\u00fcnlerinin ve numunelerin etkilenmemesi i\u00e7in 24 saat s\u0131cakl\u0131k ve nem takibi yap\u0131l\u0131yor. Bu veriler, sadece ulusal de\u011fil uluslararas\u0131 boyutta da d\u00fczenli izleniyor.<\/p>\n

Merkezin \u00e7al\u0131\u015fmalar\u0131na ili\u015fkin bilgi veren A\u00dc Hastaneler Ba\u015fhekim Yard\u0131mc\u0131s\u0131 Prof. Dr. \u00d6mer Erdeve, 1945’lere dayanan k\u00f6kl\u00fc ge\u00e7mi\u015fe sahip \u00fcniversitenin bilimsel arenada d\u00fcnya s\u0131ralamas\u0131nda yer ald\u0131\u011f\u0131n\u0131, sadece t\u0131bbi e\u011fitim de\u011fil, sa\u011fl\u0131k hizmetiyle de \u00f6n plana \u00e7\u0131kt\u0131\u011f\u0131n\u0131 s\u00f6yledi.<\/p>\n

\"\"<\/p>\n

\u00dcniversitenin \u00f6zellikle t\u0131p alan\u0131nda \u00f6nemli geli\u015fmelere yol a\u00e7abilecek bilimsel ara\u015ft\u0131rmalara imza att\u0131\u011f\u0131n\u0131 vurgulayan Erdeve, Faz-1 Klinik Ara\u015ft\u0131rma Merkezinin de Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131n\u0131n t\u00fcm denetimlerinden ge\u00e7erek Aral\u0131k 2023’te hizmete a\u00e7\u0131ld\u0131\u011f\u0131n\u0131, ulusal ve uluslararas\u0131 bilimsel projeleri y\u00fcr\u00fctmeye ba\u015flad\u0131\u011f\u0131n\u0131 ifade etti.<\/p>\n

Merkezde farkl\u0131 hastal\u0131klar i\u00e7in \u00e7al\u0131\u015fmalar e\u015f zamanl\u0131 y\u00fcr\u00fct\u00fclebilecek<\/h3>\n

Prof. Dr. Erdeve, merkezin kurulma haz\u0131rl\u0131klar\u0131n\u0131n y\u0131llar \u00f6ncesine dayand\u0131\u011f\u0131n\u0131n alt\u0131n\u0131 \u00e7izerek, “Merkezimiz \u00e7ok k\u0131sa bir s\u00fcrede uluslararas\u0131 arenadaki ilk klinik \u00e7al\u0131\u015fmas\u0131n\u0131 ald\u0131. Bu anlamda \u00e7ok mutluyuz. Buras\u0131 spesifik bir hastal\u0131\u011fa veya bilim dal\u0131na y\u00f6nelik kurulan bir merkez de\u011fil. Bir\u00e7ok alanda ayn\u0131 anda \u00e7al\u0131\u015fmalar\u0131n y\u00fcr\u00fct\u00fclebilece\u011fi bir merkez olarak dizayn edildi.” diye konu\u015ftu.<\/p>\n

\"\"<\/p>\n

Merkezde y\u00fcr\u00fct\u00fclen klinik ara\u015ft\u0131rmalar\u0131n hastalar a\u00e7\u0131s\u0131ndan \u00f6nemine i\u015faret eden Erdeve, “Faz 1 Klinik Ara\u015ft\u0131rmalar Merkezinin ana hedefi, t\u0131bb\u0131n s\u0131k\u0131nt\u0131ya girdi\u011fi, hastalar\u0131n tedaviye yan\u0131t vermedi\u011fi bir\u00e7ok hastal\u0131kta yeni ila\u00e7lar\u0131n geli\u015ftirilebilmesi i\u00e7in ilk ara\u015ft\u0131rmalar\u0131n, klinik \u00e7al\u0131\u015fmalar\u0131n yap\u0131lmas\u0131n\u0131 sa\u011flamak.” dedi.<\/p>\n

Bunun kolay bir s\u00fcre\u00e7 olmad\u0131\u011f\u0131n\u0131, klinik ara\u015ft\u0131rma \u00f6ncesi y\u0131llara dayanan laboratuvar \u00e7al\u0131\u015fmalar\u0131n\u0131n y\u00fcr\u00fct\u00fcld\u00fc\u011f\u00fcn\u00fc anlatan Erdeve, “Burada ila\u00e7lar\u0131n faydalar\u0131, dozlar\u0131n\u0131n ayarlanmas\u0131, hastalar\u0131n tedavi yan\u0131t\u0131 gibi konularda ara\u015ft\u0131rmalar yap\u0131larak hastalar\u0131m\u0131z\u0131 tedavi alabilir duruma getirmeye \u00e7al\u0131\u015f\u0131yoruz.” a\u00e7\u0131klamas\u0131nda bulundu.<\/p>\n

\u0130lk \u00e7al\u0131\u015fma, tedaviye yan\u0131t vermeyen lenfoma hastalar\u0131 i\u00e7in<\/h3>\n

A\u00dc T\u0131p Fak\u00fcltesi T\u0131bbi Farmakoloji Ana Bilim Dal\u0131 \u00d6\u011fretim \u00dcyesi ve Faz-1 Klinik Ara\u015ft\u0131rma Merkezi Sorumlusu Prof. Dr. Hakan Erg\u00fcn de \u00e7al\u0131\u015fmalar\u0131 Sorumlu Ara\u015ft\u0131rmac\u0131 Prof. Dr. Muhit \u00d6zcan ve merkez ekibinin b\u00fcy\u00fck eme\u011fiyle ger\u00e7ekle\u015ftirdiklerini belirtti.<\/p>\n

\"\"<\/p>\n

Erg\u00fcn, ilk g\u00f6n\u00fcll\u00fc taramalar\u0131na y\u00f6nelik, \u015fu bilgileri payla\u015ft\u0131:<\/p>\n

“Merkezimizde ilk \u00e7al\u0131\u015fmam\u0131z, tedaviye yan\u0131t vermeyen lenfoma hastalar\u0131na y\u00f6nelik bir ‘ak\u0131ll\u0131 ila\u00e7’ uygulamas\u0131 i\u00e7in ba\u015flat\u0131ld\u0131. Bu, lenfoman\u0131n \u00f6zel bir alt tipini kaps\u0131yor. Daha \u00f6nce en az iki farkl\u0131 tedavi uygulanm\u0131\u015f ancak yan\u0131t al\u0131namam\u0131\u015f hastalar i\u00e7in uygulanan bir ila\u00e7. Bunun klinik denemelerini ger\u00e7ekle\u015ftiriyoruz. Taramalar\u0131m\u0131z\u0131 bu hastal\u0131ktan muzdarip ve tedaviden yarar g\u00f6rme potansiyeli y\u00fcksek hastalar\u0131m\u0131zda y\u00fcr\u00fct\u00fcyoruz.”<\/p>\n

Bu uluslararas\u0131 \u00e7al\u0131\u015fman\u0131n, d\u00fcnyada ilk kez T\u00fcrkiye’deki \u00fc\u00e7 merkezde e\u015f zamanl\u0131 ba\u015flat\u0131ld\u0131\u011f\u0131n\u0131 ifade eden Erg\u00fcn, “\u015eu anda T\u00fcrkiye’de bu tedaviyle ilgili klinik \u00e7al\u0131\u015fmalar\u0131 ba\u015flatan \u00fc\u00e7 merkezden biriyiz. D\u00fcnyada ilk olman\u0131n da gururunu ya\u015f\u0131yoruz, daha sonra farkl\u0131 \u00fclkelerden merkezler de bu klinik \u00e7al\u0131\u015fmaya kat\u0131lacak.” dedi.<\/p>\n

“D\u00fcnya genelinde 160 hasta \u00e7al\u0131\u015fmaya dahil edilecek”<\/h3>\n

Prof. Dr. Erg\u00fcn, \u00f6zellikle hematolojik ve onkolojik hastal\u0131klarda, hedef odakl\u0131 ak\u0131ll\u0131 ila\u00e7lar\u0131n yo\u011fun \u015fekilde geli\u015ftirildi\u011fine dikkati \u00e7ekerek, “Biz de \u00e7al\u0131\u015fmam\u0131z kapsam\u0131nda \u015fu ana kadar 3 g\u00f6n\u00fcll\u00fc hastam\u0131z\u0131n taramas\u0131n\u0131 tamamlamak \u00fczereyiz. D\u00fcnya genelinde 160 hasta \u00e7al\u0131\u015fmaya dahil edilecek.” diye konu\u015ftu.<\/p>\n

Ak\u0131ll\u0131 ila\u00e7 \u00e7al\u0131\u015fmalar\u0131n\u0131n, tedavi yan\u0131t\u0131 al\u0131nabilece\u011fi d\u00fc\u015f\u00fcn\u00fclen az say\u0131da hasta grubuyla y\u00fcr\u00fct\u00fcld\u00fc\u011f\u00fcn\u00fcn alt\u0131n\u0131 \u00e7izen Erg\u00fcn, ilerleyen d\u00f6nemde akci\u011fer kanseri tedavisinde T\u00fcrkiye’de geri \u00f6deme kapsam\u0131nda olmayan bir ila\u00e7la ilgili \u00e7al\u0131\u015fma y\u00fcr\u00fct\u00fclece\u011fini bildirdi.<\/p>\n

T\u00fcrkiye’de geli\u015ftirilen yeni bir ila\u00e7la ilgili de sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fcler \u00fczerinde y\u00fcr\u00fct\u00fclecek \u00e7al\u0131\u015fman\u0131n g\u00f6r\u00fc\u015fmelerini s\u00fcrd\u00fcrd\u00fcklerini aktaran Erg\u00fcn, t\u00fcm bu \u00e7al\u0131\u015fmalar\u0131n ulusal ve uluslararas\u0131 alanda ciddi denetimlerden ge\u00e7tikten sonra onayland\u0131\u011f\u0131n\u0131, klinik \u00e7al\u0131\u015fma s\u00fcrecinde de her ad\u0131m\u0131n raporland\u0131\u011f\u0131n\u0131 vurgulad\u0131.<\/p>\n

Klinik ara\u015ft\u0131rmalar\u0131n uzun y\u0131llar alabilece\u011fine i\u015faret eden Erg\u00fcn, “T\u00fcm umudumuz hastalar\u0131m\u0131z\u0131n bu \u00e7al\u0131\u015fmalar sonucu geli\u015ftirilen tedavilerden yarar g\u00f6rmesi. Klinik \u00e7al\u0131\u015fmaya kat\u0131lan hastalar\u0131m\u0131z, elbette tedaviye yan\u0131t verdikleri s\u00fcre boyunca da ilac\u0131n teminiyle ilgili b\u00fcy\u00fck avantaj kazan\u0131yor.” de\u011ferlendirmesinde bulundu.<\/p>\n

Prof. Dr. Erg\u00fcn, hastalar\u0131n yarar g\u00f6rebilece\u011fi bu \u00e7al\u0131\u015fmalar\u0131 ger\u00e7ekle\u015ftirmenin hem mutluluk hem de gurur verici oldu\u011funu dile getirdi.<\/p>\n


\n
\n Anadolu Ajans\u0131 web sitesinde, AA Haber Ak\u0131\u015f Sistemi (HAS) \u00fczerinden abonelere sunulan haberler, \u00f6zetlenerek yay\u0131mlanmaktad\u0131r. Abonelik i\u00e7in l\u00fctfen ileti\u015fime ge\u00e7iniz.<\/b>
\n <\/a>
\n <\/span>\n <\/div>\n